Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Teijin Medical Technologies Co., Ltd.

https://teijin-medical.co.jp/en/

Latest From Teijin Medical Technologies Co., Ltd.

Japan Nods Include Global Firsts For Duvroq, Vafseo And First Local Biosimilar Humira

Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, two world-first nods for the country’s second HIF-PH inhibitors and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.

Japan Approvals

New $90M Medtech Convergence Fund Will Focus On Home Technologies

SV Health Investors has launched a new $90m venture fund to develop early-stage medtech start-ups. The fund has received investment from Japanese technology group Tejin.

Innovation Financing

Open-Label Extensions The Key To Gantenerumab Success, Stresses Roche

Roche’s neuroscience strategy of following the science, taking on lessons from open label extensions from Phase III studies, is vital to the success of gantenerumab, the company said in an interview with Scrip.

Clinical Trials Neurology

Surprising SanBio/Sumitomo Stroke Stumble Slams Stocks

Mesenchymal stem cell-based therapy's missed Phase IIb endpoint in stroke prompts both an assessment of future development plans and a precipitous fall in developers' stocks.

Japan Regenerative Medicine
See All

Company Information

  • Industry
  • Medical Devices
  • Other Names / Subsidiaries
    • Teijin Nakashima Medical Co. Ltd.
UsernamePublicRestriction

Register